Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement

Laura S. Hiemcke-JiwaDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands; Correspondence[email protected]

Roos J. LeguitDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands;

Joyce H. Radersma-van LoonDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands;

Peter E. WesterweelDepartment of Internal Medicine, Albert Schweitzer hospital Dordrecht, Dordrecht, The Netherlands;

Johannes J. M. RoodDepartment of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Faculty of Science, Utrecht, The Netherlands;

Jeanette K. DoorduijnDepartment of Hematology, Erasmus Cancer Institute Rotterdam, Rotterdam, The Netherlands;

Manon M. H. HuibersDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands;

Monique C. MinnemaDepartment of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands

show all

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement

ICMJE Form for Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date